Welcome to our dedicated page for Viatris news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris stock.
Viatris Inc. reports developments for a global healthcare company with a portfolio spanning generics, established brands and innovative medicines. News commonly covers quarterly results, guidance, cash deployment, dividends, capital allocation and management changes, alongside product launches and pipeline updates across major therapeutic areas.
Company updates also include scientific presentations and regulatory actions tied to specific medicines and candidates, including Effexor in Japan, ophthalmology programs such as phentolamine ophthalmic solution and RYZUMVI, and an investigational low-dose estrogen combined hormonal contraceptive weekly patch. Viatris was formed through the combination of Mylan and Pfizer's Upjohn business and operates with global centers in the U.S., China and India.
Viatris (Nasdaq: VTRS) announced six abstracts on its investigational low-dose estrogen combined hormonal contraceptive (MR-100A-01) will be presented at the ACOG 2026 Annual Clinical & Scientific Meeting in Washington, D.C., May 1–3, 2026. Presentations include positive Phase 3 efficacy and safety results, adhesion and pharmacokinetic data, and cycle control findings. Sessions and times for six electronic poster presentations and an educational symposium supported by Viatris are listed; Viatris will be at booth #223.
Viatris (Nasdaq: VTRS) will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a live webcast at 8:30 a.m. ET the same day to discuss results.
Investors can access the live webcast at investor.viatris.com, call 844.308.3344 (domestic) or 412.317.1896 (international). A replay will be available on the company website after the call.
Viatris (Nasdaq: VTRS) will present four abstracts at the ASCRS Annual Meeting in Washington, D.C., April 10–13, 2026, covering ophthalmology data including full VEGA-3 Phase 3 results for MR-141, a Phase 1 varenicline nasal spray study in Japanese adults, and analyses of RYZUMVI and MR-142.
Presentations include oral and electronic posters; Viatris also provided an independent educational grant for a symposium on April 11, 6:00–7:30 p.m. ET, and will staff booth #233.
Viatris (Nasdaq: VTRS) announced MHLW approval of Effexor SR 37.5 mg / 75 mg for adults with generalized anxiety disorder (GAD) in Japan on March 23, 2026.
This makes Effexor the first and only approved GAD treatment in Japan; approval is supported by a Phase 3 trial (p=0.012) and long-term extension data.
Viatris (Nasdaq: VTRS) outlined a strategic plan and financial framework aimed at delivering sustained revenue and earnings growth through 2030. Key numerical targets include 5%-6% total revenues CAGR, 7%-8% adjusted EBITDA CAGR, 9%-10% adjusted EPS CAGR and > $3.0B free cash flow in 2030.
The company expects > $11 billion in cash available for deployment through 2030, identified ≈ $650 million gross cost savings, and highlighted near-term launches and pipeline assets (selatogrel, cenerimod) as potential upside drivers.
Viatris (Nasdaq: VTRS) reported Q4 2025 total revenues of $3.7B and FY2025 total revenues of $14.3B, met or exceeded 2025 guidance across key metrics, and returned over $1B to shareholders. The company completed an enterprise strategic review, expects up to $650M in net cost savings, and provided 2026 guidance while noting multiple upcoming regulatory milestones and an expected workforce reduction of up to 10%.
Key financials: Q4 adjusted EBITDA of $1.003B, Q4 adjusted EPS of $0.57, FY adjusted EBITDA of $4.16B, FY free cash flow of $1.94B, and a FY U.S. GAAP net loss of $(3.51B) reflecting a $2.9B goodwill impairment.
Viatris (Nasdaq: VTRS) announced its 2026 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 per share. The dividend is payable on March 18, 2026 to shareholders of record as of March 9, 2026.
This marks the sixth consecutive year the company has paid a dividend.
Viatris (Nasdaq: VTRS) announced FDA acceptance of the supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, with a PDUFA goal date of October 17, 2026. The sNDA is supported by positive Phase 3 VEGA-2 and VEGA-3 results that met primary and all key secondary endpoints with no treatment-related serious adverse events.
Ryzumvi (phentolamine 0.75%) is already approved in the U.S. for pharmacologically-induced mydriasis; the sNDA seeks to expand the indication to include presbyopia. VEGA-3 data will be presented at ASCRS in April and ARVO in May.
Viatris (Nasdaq: VTRS) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a live webcast at 8:30 a.m. ET the same day. A replay will be available on the investor website.
Viatris also will host an Investor Event in New York City on March 19, 2026; additional details and pre-registration information will be provided during the February 26 investor call.
Viatris (Nasdaq: VTRS) appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, with outgoing CLO Brian Roman remaining as advisor through April 1, 2026.
Maletta brings nearly 30 years of legal experience in branded and generic pharmaceuticals, including leadership roles at Endo and Allergan and involvement in a $70 billion Allergan transaction.